Biotechnology company Accure Therapeutics recently hit a major milestone by securing a substantial $1.6 million in funding. The financial support came from two esteemed organizations – the Michael J. Fox Foundation and the Luxembourg National Research Fund.
This funding marks a significant step forward for Accure Therapeutics, underscoring confidence in the company’s strong scientific foundation and research and development plans for their drug candidate, ACT-02. This particular drug holds immense promise in addressing critical unmet needs within the realm of Parkinson’s disease.
### A Closer Look at ACT-02
ACT-02 is no ordinary drug candidate; it represents a novel approach with disease-modifying potential. By targeting Prolyl Endopeptidase (PREP), an underexplored aspect of Parkinson’s disease management, ACC-02 shows great promise in transforming treatment strategies for this debilitating condition.
“Parkinson’s is the second most common neurodegenerative disease globally, affecting over ten million individuals worldwide,” remarked a spokesperson from Accure Therapeutics. “With numbers expected to swell to 1.2 million by 2030 in the US alone, innovative solutions like ACT-02 are urgently needed.”
### Unveiling Promising Data
The development of ACT-02 has seen notable progress, with encouraging efficacy data emerging from preclinical trials involving Parkinson’s disease models. The comprehensive positive results have provided a strong foundation for further advancements in this groundbreaking project.
Insightful Grants Fueling Innovation
Accure Therapeutics received a generous grant of €1.02 million from The Michael J. Fox Foundation for Parkinson’s Research to propel their ambitious project titled ‘ACT-02 as a disease-modifying therapy for Parkinson’s.’ This collaboration aims to push boundaries and pave the way for transformative treatments that directly impact patients’ lives.
Prof Dr Franziska Richter Assencio shared insights into their research endeavors: “Our team is excited about delving deeper into studying ACT-02, which has already showcased promising effects on neuronal protection and cognitive function improvement in experimental models.”
Empowering Partnerships through FNR Grant
Further reinforcing their commitment to innovation, Accure Therapeutics was awarded an additional grant through the FNR BRIDGES program managed by the Luxembourg National Research Fund (FNR). This partnership focuses on leveraging public-private collaborations to advance precision medicine strategies tailored specifically for Parkinson’s disease patients.
Laurent Nguyen, co-founder and CEO at Accure Therapeutics expressed gratitude stating, “These grants mark significant strides towards developing our pioneering drug candidate – ACT-02 – aiming to revolutionize how we treat individuals battling with Parkinson’s Disease.”
In conclusion, these grants not only provide crucial financial backing but also symbolize collective efforts towards pioneering medical breakthroughs that could potentially transform the landscape of Parkinson’s disease treatment.
Leave feedback about this